An Interventional Phase Ib/II Study to Evaluate the Safety and Efficacy of PF-08634404 Monotherapy and in Combination with Other Anticancer Agents in Adult Participants with Locally Advanced or Metastatic Renal Cell Carcinoma

Clinical Trial Information

Trial Phone: 321-841-7246

Principal Investigator: Jad Chahoud, MD

Phase: I/II

Age Group: ADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT07227415

Objective

PF-08634404 is being studied to see how well it works to shrink or control cancer when used alone. The study will also evaluate how safe the treatment is and how well patients tolerate it. Doctors will closely monitor tumor response and any side effects during treatment.

Share:

Related Clinical Trials

Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy Followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: A Double-Blind Phase III Study
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Percutaneous or Endoscopic Gallbladder Drainage: The PEG Trial
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL GROUP, MULTICENTER STUDY WITH OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF FENFLURAMINE HYDROCHLORIDE IN STUDY PARTICIPANTS WITH RETT SYNDROME